AR Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

AR Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,000	Closed	-$321K	–	120
2017 Q1	$321K	Hold	10,000	–	–	0.13%	106
2016 Q4	$363K	Hold	10,000	–	–	0.15%	99
2016 Q3	$460K	Hold	10,000	–	–	0.2%	92
2016 Q2	$502K	Hold	10,000	–	–	0.21%	89
2016 Q1	$535K	Hold	10,000	–	–	0.23%	82
2015 Q4	$656K	Hold	10,000	–	–	0.3%	72
2015 Q3	$565K	Hold	10,000	–	–	0.25%	83
2015 Q2	$591K	Hold	10,000	–	–	0.24%	81
2015 Q1	$623K	Hold	10,000	–	–	0.25%	76
2014 Q4	$575K	Hold	10,000	–	–	0.23%	79
2014 Q3	$537K	Hold	10,000	–	–	0.22%	79
2014 Q2	$524K	Hold	10,000	–	–	0.21%	84
2014 Q1	$528K	Hold	10,000	–	–	0.22%	80
2013 Q4	$401K	Hold	10,000	–	–	0.17%	89
2013 Q3	$378K	Hold	10,000	–	–	0.17%	91
2013 Q2	$392K	Buy	+10,000	New	+$389K	0.18%	87

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AR Asset Management's TEVA Position: Q2 2017 in Review

AR Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 10,000 shares — an estimated $321K sold.

AR Asset Management first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $656K in Q4 2015. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

AR Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
AR Asset Management sold 10,000 Teva Pharmaceuticals shares in Q2 2017, an estimated $321K.
AR Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
AR Asset Management's Teva Pharmaceuticals position peaked at $656K in Q4 2015.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on AR Asset Management's 13F filing for Q2 2017, filed 7 Aug 2017.